The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer

Jörg Kleeff, Toshiyuki Ishiwata, Asli Kumbasar, Helmut Friess, Markus W. Büchler, Arthur D. Lander, Murray Korc

Research output: Contribution to journalArticle

252 Citations (Scopus)

Abstract

Heparan sulfate proteoglycans (HSPGs) play diverse roles in cell recognition, growth, and adhesion. In vitro studies suggest that cell- surface HSPGs act as coreceptors for heparin-binding mitogenic growth factors. Here we show that the glycosylphosphatidylinositol- (GPI-) anchored HSPG glypican-1 is strongly expressed in human pancreatic cancer, both by the cancer cells and the adjacent fibroblasts, whereas expression of glypican-1 is low in the normal pancreas and in chronic pancreatitis. Treatment of two pancreatic cancer cell lines, which express glypican-1, with the enzyme phosphoinositide-specific phospholipase-C (PI-PLC) abrogated their mitogenic responses to two heparin-binding growth factors that are commonly overexpressed in pancreatic cancer: fibroblast growth factor 2 (FGF2) and heparin-binding EGF-like growth factor (HB-EGF). PI-PLC did not alter the response to the non-heparin-binding growth factors EGF and IGF-1. Stable expression of a form of glypican-1 engineered to possess a transmembrane domain instead of a GPI anchor conferred resistance to the inhibitory effects of PI-PLC on growth factor responsiveness. Furthermore, transfection of a glypican-1 antisense construct attenuated glypican-1 protein levels and the mitogenic response to FGF2 and HB-EGF. We propose that glypican-1 plays an essential role in the responses of pancreatic cancer cells to certain mitogenic stimuli, that it is relatively unique in relation to other HSPGs, and that its expression by pancreatic cancer cells may be of importance in the pathobiology of this disorder.

Original languageEnglish (US)
Pages (from-to)1662-1673
Number of pages12
JournalJournal of Clinical Investigation
Volume102
Issue number9
StatePublished - Nov 1 1998
Externally publishedYes

Fingerprint

Glypicans
Heparan Sulfate Proteoglycans
Pancreatic Neoplasms
Intercellular Signaling Peptides and Proteins
Phosphoinositide Phospholipase C
Fibroblast Growth Factor 2
Heparin
Glycosylphosphatidylinositols
Chronic Pancreatitis
Pancreatic Carcinoma
Insulin-Like Growth Factor I
Epidermal Growth Factor
Transfection
Pancreas
Fibroblasts
Cell Line
Enzymes

Keywords

  • Cancer
  • Glypican-1
  • Growth factors
  • Heparin binding
  • Pancreas

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. / Kleeff, Jörg; Ishiwata, Toshiyuki; Kumbasar, Asli; Friess, Helmut; Büchler, Markus W.; Lander, Arthur D.; Korc, Murray.

In: Journal of Clinical Investigation, Vol. 102, No. 9, 01.11.1998, p. 1662-1673.

Research output: Contribution to journalArticle

Kleeff, Jörg ; Ishiwata, Toshiyuki ; Kumbasar, Asli ; Friess, Helmut ; Büchler, Markus W. ; Lander, Arthur D. ; Korc, Murray. / The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. In: Journal of Clinical Investigation. 1998 ; Vol. 102, No. 9. pp. 1662-1673.
@article{591578421df342f48d6b193e2db12235,
title = "The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer",
abstract = "Heparan sulfate proteoglycans (HSPGs) play diverse roles in cell recognition, growth, and adhesion. In vitro studies suggest that cell- surface HSPGs act as coreceptors for heparin-binding mitogenic growth factors. Here we show that the glycosylphosphatidylinositol- (GPI-) anchored HSPG glypican-1 is strongly expressed in human pancreatic cancer, both by the cancer cells and the adjacent fibroblasts, whereas expression of glypican-1 is low in the normal pancreas and in chronic pancreatitis. Treatment of two pancreatic cancer cell lines, which express glypican-1, with the enzyme phosphoinositide-specific phospholipase-C (PI-PLC) abrogated their mitogenic responses to two heparin-binding growth factors that are commonly overexpressed in pancreatic cancer: fibroblast growth factor 2 (FGF2) and heparin-binding EGF-like growth factor (HB-EGF). PI-PLC did not alter the response to the non-heparin-binding growth factors EGF and IGF-1. Stable expression of a form of glypican-1 engineered to possess a transmembrane domain instead of a GPI anchor conferred resistance to the inhibitory effects of PI-PLC on growth factor responsiveness. Furthermore, transfection of a glypican-1 antisense construct attenuated glypican-1 protein levels and the mitogenic response to FGF2 and HB-EGF. We propose that glypican-1 plays an essential role in the responses of pancreatic cancer cells to certain mitogenic stimuli, that it is relatively unique in relation to other HSPGs, and that its expression by pancreatic cancer cells may be of importance in the pathobiology of this disorder.",
keywords = "Cancer, Glypican-1, Growth factors, Heparin binding, Pancreas",
author = "J{\"o}rg Kleeff and Toshiyuki Ishiwata and Asli Kumbasar and Helmut Friess and B{\"u}chler, {Markus W.} and Lander, {Arthur D.} and Murray Korc",
year = "1998",
month = "11",
day = "1",
language = "English (US)",
volume = "102",
pages = "1662--1673",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "9",

}

TY - JOUR

T1 - The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer

AU - Kleeff, Jörg

AU - Ishiwata, Toshiyuki

AU - Kumbasar, Asli

AU - Friess, Helmut

AU - Büchler, Markus W.

AU - Lander, Arthur D.

AU - Korc, Murray

PY - 1998/11/1

Y1 - 1998/11/1

N2 - Heparan sulfate proteoglycans (HSPGs) play diverse roles in cell recognition, growth, and adhesion. In vitro studies suggest that cell- surface HSPGs act as coreceptors for heparin-binding mitogenic growth factors. Here we show that the glycosylphosphatidylinositol- (GPI-) anchored HSPG glypican-1 is strongly expressed in human pancreatic cancer, both by the cancer cells and the adjacent fibroblasts, whereas expression of glypican-1 is low in the normal pancreas and in chronic pancreatitis. Treatment of two pancreatic cancer cell lines, which express glypican-1, with the enzyme phosphoinositide-specific phospholipase-C (PI-PLC) abrogated their mitogenic responses to two heparin-binding growth factors that are commonly overexpressed in pancreatic cancer: fibroblast growth factor 2 (FGF2) and heparin-binding EGF-like growth factor (HB-EGF). PI-PLC did not alter the response to the non-heparin-binding growth factors EGF and IGF-1. Stable expression of a form of glypican-1 engineered to possess a transmembrane domain instead of a GPI anchor conferred resistance to the inhibitory effects of PI-PLC on growth factor responsiveness. Furthermore, transfection of a glypican-1 antisense construct attenuated glypican-1 protein levels and the mitogenic response to FGF2 and HB-EGF. We propose that glypican-1 plays an essential role in the responses of pancreatic cancer cells to certain mitogenic stimuli, that it is relatively unique in relation to other HSPGs, and that its expression by pancreatic cancer cells may be of importance in the pathobiology of this disorder.

AB - Heparan sulfate proteoglycans (HSPGs) play diverse roles in cell recognition, growth, and adhesion. In vitro studies suggest that cell- surface HSPGs act as coreceptors for heparin-binding mitogenic growth factors. Here we show that the glycosylphosphatidylinositol- (GPI-) anchored HSPG glypican-1 is strongly expressed in human pancreatic cancer, both by the cancer cells and the adjacent fibroblasts, whereas expression of glypican-1 is low in the normal pancreas and in chronic pancreatitis. Treatment of two pancreatic cancer cell lines, which express glypican-1, with the enzyme phosphoinositide-specific phospholipase-C (PI-PLC) abrogated their mitogenic responses to two heparin-binding growth factors that are commonly overexpressed in pancreatic cancer: fibroblast growth factor 2 (FGF2) and heparin-binding EGF-like growth factor (HB-EGF). PI-PLC did not alter the response to the non-heparin-binding growth factors EGF and IGF-1. Stable expression of a form of glypican-1 engineered to possess a transmembrane domain instead of a GPI anchor conferred resistance to the inhibitory effects of PI-PLC on growth factor responsiveness. Furthermore, transfection of a glypican-1 antisense construct attenuated glypican-1 protein levels and the mitogenic response to FGF2 and HB-EGF. We propose that glypican-1 plays an essential role in the responses of pancreatic cancer cells to certain mitogenic stimuli, that it is relatively unique in relation to other HSPGs, and that its expression by pancreatic cancer cells may be of importance in the pathobiology of this disorder.

KW - Cancer

KW - Glypican-1

KW - Growth factors

KW - Heparin binding

KW - Pancreas

UR - http://www.scopus.com/inward/record.url?scp=0032213027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032213027&partnerID=8YFLogxK

M3 - Article

C2 - 9802880

AN - SCOPUS:0032213027

VL - 102

SP - 1662

EP - 1673

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 9

ER -